Neurobiology of Aging
Volume 31, Issue 10 , Pages 1743-1757 , October 2010

Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease

  • Verónica Berta Dorfman

      Affiliations

    • Fundación Instituto Leloir - Instituto de Investigaciones Bioquímicas Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Patricias Argentinas 435, C1405BWE, Ciudad Autónoma de Buenos Aires, Argentina
    • ,
  • Laura Pasquini

      Affiliations

    • Departamento de Química Biológica, Instituto de Química y Fisicoquímica Biológica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, CONICET, Junín 954, C1121ABG, Ciudad Autónoma de Buenos Aires, Argentina
    • ,
  • Miguel Riudavets

      Affiliations

    • Department of Neuropathology, Institute for Neurological Research, FLENI, C1428AQK, Montañeses 2325, Ciudad Autónoma de Buenos Aires, Argentina
    • ,
  • Juan José López-Costa

      Affiliations

    • Instituto de Biología Celular y Neurociencia Prof. E. De Robertis, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, P3, (C1121ABG), Ciudad Autónoma de Buenos Aires, Argentina
    • ,
  • Andrés Villegas

      Affiliations

    • Neuroscience Group of Antioquia, Department of Internal Medicine, Clinical Neurology Service, School of Medicine, University of Antioquia, Calle 62 #52-72, 3301, Medellin, Colombia
    • ,
  • Juan Carlos Troncoso

      Affiliations

    • Department of Pathology (Neuropathology), Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States
    • ,
  • Francisco Lopera

      Affiliations

    • Neuroscience Group of Antioquia, Department of Internal Medicine, Clinical Neurology Service, School of Medicine, University of Antioquia, Calle 62 #52-72, 3301, Medellin, Colombia
    • ,
  • Eduardo Miguel Castaño

      Affiliations

    • Fundación Instituto Leloir - Instituto de Investigaciones Bioquímicas Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Patricias Argentinas 435, C1405BWE, Ciudad Autónoma de Buenos Aires, Argentina
    • ,
  • Laura Morelli

      Affiliations

    • Fundación Instituto Leloir - Instituto de Investigaciones Bioquímicas Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Patricias Argentinas 435, C1405BWE, Ciudad Autónoma de Buenos Aires, Argentina
    • Corresponding Author InformationCorresponding author at: Ave. Patricias Argentinas 435, C1405BWE Ciudad Autónoma de Buenos Aires, Argentina. Tel.: +54 11 5238 7500; fax: +54 11 5238 7501.

Received 23 October 2007 ,Revised 23 July 2008 ,Accepted 26 September 2008.

References 

  1. Akiyama H, Kondo H, Ikeda K, Kato M, McGeer PL. Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res. 2001;902:277–281
  2. Apelt J, Ach K, Schliebs R. Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci. Lett. 2003;339:183–186
  3. Bernstein HG, Ansorge S, Riederer P, Reiser M, Frölich L, Bogerts B. Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci. Lett. 1999;263:161–164
  4. Box GEP, Cox DR. An analysis of transformations (with discussion). J. R. Stat. Soc. B. 1964;26:211–252
  5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259
  6. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 1986;19:253–262
  7. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol. Aging. 2005;26:645–654
  8. Castaño EM, Prelli F, Soto C, Beavis R, Matsubara E, Shoji M, et al. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J. Biol. Chem. 1996;271:32185–32191
  9. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am. J. Pathol. 2003;162:313–319
  10. Cullen KM, Kócsi Z, Stone J. Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol. Aging. 2006;27:1786–1796
  11. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387–390
  12. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology. 2002;59:398–407
  13. Dewachter I, Van Dorpe J, Smeijers L, Gilis M, Kuiperi C, Laenen I, et al. Aging increased amyloid β peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin 1. J. Neurosci. 2000;20:6452–6458
  14. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid betaprotein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 2003;100:4162–4167
  15. Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, et al. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci. Res. 2002;43:39–56
  16. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Younkin LH, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 1995;270:7013–7016
  17. Güntert A, Döbeli H, Bohrmann B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience. 2006;143:461–475
  18. Hartmann T. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci. 2001;24:S45–48
  19. Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK, et al. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J. Neurosci. 2002;22:10083–10087
  20. Haass C, De Strooper B. The presenilins in Alzheimer's disease—proteolysis holds the key. Science. 1999;286:916–919
  21. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Abeta by neprilysin. Science. 2001;292:1550–1552
  22. Jellinger KA. Vascular-ischemic dementia: an update. J. Neural. Transm. Suppl. 2002;62:1–23
  23. Jeynes B, Provias J. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. Acta Neuropathol. 2006;112:417–427
  24. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, et al. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry. 2002;41:922–928
  25. Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, et al. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J. Biol. Chem. 2007;282:7825–7832
  26. Kuo WL, Gehm BD, Rosner MR, Li W, Keller G. Inducible expression and cellular localization of insulin-degrading enzyme in a stably transfected cell line. J. Biol. Chem. 1994;269:22599–22606
  27. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 2001;276:12991–12998
  28. Leal MC, Dorfman VB, Gamba AF, Frangione B, Wisniewski T, Castaño EM, et al. Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J. Neuropathol. Exp. Neurol. 2006;65:976–987
  29. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087–1093
  30. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, et al. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat. Med. 1996;2:1146–1150
  31. Levy E, Carman MD, Fernandez-Madrid I, Power MD, Lieberburg I, van Duinen SG, et al. Science. 1990;248:1124–1126
  32. Liu K, Solano I, Mann D, Lemere C, Mercken M, Trojanowski JQ, et al. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol. 2006;112:163–174
  33. Maurer K, Hoyer S. Alois Alzheimer revisited: differences in origin of the disease carrying his name. J. Neural. Transm. 2006;113:1645–1658
  34. Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 2006;65:1012–1021
  35. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479–486
  36. Morelli L, Llovera R, Gonzalez SA, Affranchino JL, Prelli F, Frangione B, et al. Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J. Biol. Chem. 2003;278:23221–23226
  37. Morelli L, Llovera RE, Mathov I, Lue LF, Frangione B, Ghiso J, et al. Insulin degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy. Biol. Chem. 2004;279:56004–56013
  38. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61:199–205
  39. Perez A, Morelli L, Cresto JC, Castaño EM. Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res. 2000;25:247–255
  40. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol. Aging. 2005;26:355–361
  41. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, et al. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993;90:10836–10840
  42. Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, et al. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol. Med. 2003;9:112–122
  43. Roses AD. Genetic testing for Alzheimer disease. Practical and ethical issues. Arch. Neurol. 1997;54:1226–1229
  44. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996;2:864–870
  45. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N.Y. Acad. Sci. 2000;924:17–25
  46. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem. 2003;85:1581–1591
  47. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J. Clin. Invest. 2000;106:1489–1499
  48. Sjöbeck M, Haglund M, Englund E. Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease—a neuropathological study. Int. J. Geriatr. Psychiatry. 2005;20:919–926
  49. Turner AJ, Fisk L, Nalivaeva NN. Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. Ann. N.Y. Acad. Sci. 2004;1035:1–20
  50. van Duinen SG, Castaño EM, Prelli F, Bots GTAB, Luyendijk W, Frangione B. Proc. Natl. Acad. Sci. U.S.A. 1987;84:5991–5994
  51. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735–741
  52. Wang DS, Iwata N, Hama E, Saido TC, Dickson DW. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 2003;310:236–241
  53. Webster B, Hansen L, Adame A, Crews L, Torrance M, Thal L, et al. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006;65:142–151
  54. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513–517
  55. Yakoshima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 2001;297:97–100
  56. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, Pasinetti GM. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol. Aging. 2007;6:824–830

PII: S0197-4580(08)00351-5

doi: 10.1016/j.neurobiolaging.2008.09.016

Neurobiology of Aging
Volume 31, Issue 10 , Pages 1743-1757 , October 2010

Article Tools

* Image Usage & Resolution